0001209191-21-049368.txt : 20210803 0001209191-21-049368.hdr.sgml : 20210803 20210803165146 ACCESSION NUMBER: 0001209191-21-049368 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210803 FILED AS OF DATE: 20210803 DATE AS OF CHANGE: 20210803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FAIRBAIRN EMILY CENTRAL INDEX KEY: 0001682638 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39692 FILM NUMBER: 211140622 MAIL ADDRESS: STREET 1: 10 ORINDA VIEW ROAD CITY: ORINDA STATE: CA ZIP: 94563 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Transcend Partners Opportunity Fund LLC CENTRAL INDEX KEY: 0001832019 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39692 FILM NUMBER: 211140621 BUSINESS ADDRESS: STREET 1: 10 ORINDA VIEW ROAD CITY: ORINDA STATE: CA ZIP: 94563 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: 10 ORINDA VIEW ROAD CITY: ORINDA STATE: CA ZIP: 94563 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IN8BIO, INC. CENTRAL INDEX KEY: 0001740279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825462585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 79 MADISON AVENUE, 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: 79 MADISON AVENUE, 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Incysus Therapeutics, Inc. DATE OF NAME CHANGE: 20180510 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-03 0 0001740279 IN8BIO, INC. INAB 0001682638 FAIRBAIRN EMILY 10 ORINDA VIEW ROAD ORINDA CA 94563 1 0 1 0 0001832019 Transcend Partners Opportunity Fund LLC 10 ORINDA VIEW ROAD ORINDA CA 94563 0 0 1 0 Common Stock 2021-08-03 4 C 0 83124 A 91336 I See footnote Common Stock 2021-08-03 4 C 0 27706 A 27706 I See footnote Common Stock 2021-08-03 4 C 0 3222485 A 3222485 I See footnote Common Stock 2021-08-03 4 P 0 100000 10.00 A 3322485 I See footnote Series A Preferred Stock 2021-08-03 4 C 0 75588 0.00 D Common Stock 83124 0 I See footnote Series A Preferred Stock 2021-08-03 4 C 0 25195 0.00 D Common Stock 27706 0 I See footnote Series A Preferred Stock 2021-08-03 4 C 0 2930332 0.00 D Common Stock 3222485 0 I See footnote Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering. The securities are held by Valley High Limited Partnership ("Valley High"). Emily Fairbairn is the sole managing partner of Valley High and has voting and investment power over the shares held by Valley High. The securities are held by Emily T. Fairbairn Roth IRA ("Roth IRA"). Emily Fairbairn exercises control over the Roth IRA, and as such, has voting and investment power over the shares held by the Roth IRA. The securities are held by Transcend Partners Opportunity Fund LLC ("Transcend"). Emily Fairbairn is the sole managing member of Transcend and has voting and investment power over the shares held by Transcend. /s/ Jason Minio, Attorney-in-Fact 2021-08-03 /s/ Jason Minio, Attorney-in-Fact 2021-08-03